PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20663036-12	2010	Moreover, beta-elemene exposure resulted in a decreased Bcl-2 protein level, increased cytochrome c release, and activated PARP and caspase-3, -7, -9, and -10 in prostate cancer cells.	beta-elemene	10-22	caspase 3	Homo sapiens	132-158	
25556484-7	2014	Real-time quantitative PCR and Western-blotting assay were performed to investigated the influence of beta-elemene on expression levels of Fas/FasL, caspase-3, Bcl-2 and Bax.	beta-elemene	102-114	caspase 3	Homo sapiens	149-158	
25556484-12	2014	Activation of caspase-3,-8 and -9 was increased and the pro-apoptotic factors Fas/FasL and Bax were upregulated, while the anti-apoptotic Bcl-2 was downregulated after treatment with beta-elemene at both mRNA and protein levels.	beta-elemene	183-195	caspase 3	Homo sapiens	14-33	
22843880-9	2012	Moreover, beta-elemene triggered apoptosis and irreversible cell death in both sensitive and resistant ovarian cancer cells via the activation of caspase-3, -8 and 9; the loss of mitochondrial membrane potential (deltaPsim); the release of cytochrome c into the cytosol; and changes in the expression of BCL-2 family proteins.	beta-elemene	10-22	caspase 3	Homo sapiens	146-165	
22545969-7	2010	beta-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X(L)  expression, and release of cytochrome c from mitochondria in these cells.	beta-elemene	0-12	caspase 3	Homo sapiens	59-73	
22545969-7	2010	beta-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X(L)  expression, and release of cytochrome c from mitochondria in these cells.	beta-elemene	0-12	caspase 3	Homo sapiens	101-117	
23564782-6	2013	beta-Elemene-enhanced cisplatin cytotoxicity was associated with increased apoptotic cell death, as determined by DNA fragmentation, and increased activities of caspase-3, -7, -8, -9, and -10 in bladder cancer cell lines.	beta-elemene	0-12	caspase 3	Homo sapiens	161-191	
19513519-6	2009	Finally, beta-elemene augmented the cisplatin-induced increases in caspase-3, -7, -9 and -10 activities and cleaved caspase-3, -9 and poly(ADP-ribose) polymerase levels in NSCLC cells.	beta-elemene	9-21	caspase 3	Homo sapiens	67-92	
20416170-4	2010	The effects of beta-elemene on the expression of BCL-2, caspase-3, DR-4 and NF-kappaB P65 proteins were analyzed by Western blot.	beta-elemene	15-27	caspase 3	Homo sapiens	56-65	
20416170-7	2010	The expression of caspase-3 and DR-4 proteins in RPMI-8226 cells treated with beta-elemene increased in a time-dependent manner, while expressions of BCL-2 and NF-kappaB P65 proteins decreased.	beta-elemene	78-90	caspase 3	Homo sapiens	18-27	
34257541-5	2021	Incubation of these cells with beta-elemene led to the activation of caspase-3 and generation of reactive oxygen species (ROS).	beta-elemene	31-43	caspase 3	Homo sapiens	69-78	
26721344-6	2016	beta-Elemene-treated FLS showed a significant decline in mitochondrial membrane potential, an accumulation of cytochrome c in the cytosol, and increased activities of caspase-9 and caspase-3.	beta-elemene	0-12	caspase 3	Homo sapiens	181-190	
28355175-8	2017	Cisplatin combined with beta-elemene decreased the expressions of p-STAT3, p-JAK2, and Bcl-2, and increased the expressions of Bax and caspase-3 significantly compared to cisplatin only treatment, as well as in the xenograft model.	beta-elemene	24-36	caspase 3	Homo sapiens	135-144